Analyst picks & changes

Agouron Pharmaceuticals Inc.

Edward Hurwitz of Smith Barney reiterated a "buy" (venture) on Agouron Pharmaceuticals Inc., noting that preliminary pharmacokinetics data on the company's HIV protease inhibitors suggest that the compounds may be as good or better than many of the HIV protease inhibitors under development elsewhere. ...